Team Leader : André Pèlegrin
Institut de Recherche en
Cancérologie de Montpellier
CRLC Val d’Aurelle-Paul Lamarque
34298 Montpellier cedex 5
|
|
Tél. : 33 (0)4 67 61 30 32
Fax : 33 (0)4 67 61 37 87
andre.pelegrin@inserm.fr |
Research topics
The research topic of our team deals with the design, development and in vivo use of antibodies, peptides and derived molecules for cancer diagnosis, cancer therapy, and the study of their combination with ionizing radiations.
Our goal is to exploit the recognition specificity of antibodies or peptides for a target tumor. In oncology, the target can be an associated tumor antigen, a growth factor receptor, the product of an oncogene or of a "tumor suppressor" mutated gene, or even a molecule involved in angiogenesis..
more informations ...
|
|
Main Publications
Chentouf M, Rigo M, Ghannam S, Navarro-Teulon I, Mongrand S, Pèlegrin A, Chardès T. The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts. Immunol Lett. 2010 Jul 23. [Epub ahead of print]
Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Télécharger l'article :  
Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, Pèlegrin M, Navarro-Teulon I, Pèlegrin A, Pouget JP. Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis. J Nucl Med. 2009 Nov 12. [Epub ahead of print]
Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol. 2009 Nov 4. [Epub ahead of print]
more informations ...
|
